Does the bleomycin sensitivity assay express cancer phenotype?
Authors:
- Éva RemenárÉRÉva Remenár
- Miklós KáslerMKMiklós Kásler
- Sarolta GundySGSarolta Gundy
Open Access
- 1 January 2003
- journal article
- research article
- Published by Oxford University Press (OUP) in Mutagenesis
- Vol. 18 (1) , 59-63
Abstract
The bleomycin (BLM) sensitivity assay has been associated with the measuring of increased risk of individual susceptibility to cancer, when chromatid breaks per cell (b/c) induced by an in vitro treatment of lymphocytes with BLM are elevated. The high heritability of BLM sensitivity indicates a genetic background. We wished to clarify whether the test characterizes the head and neck cancer phenotype as compared not only with healthy individuals, but also with alcoholic patients (ALCs) whose exposure to tobacco and alcohol consumption were similar to that of head and neck cancer patients (HNCPs), but whose liver diseases were not cancerous. If the BLM test quantifies merely cancer susceptibility on an inherited basis, the mutagen sensitivity of HNCPs should differ from that of ALCs. Conventional chromosome analysis and the BLM assay were carried out on 156 HNCPs, 51 ALCs, 146 healthy non-smokers and non-drinkers and 149 non-drinking smokers. The spontaneous rates of chromosomal aberrations (CAs) in HNCPs, ALCs and healthy smokers were identical (2.8%), but differed significantly from the non-smoking controls (2.25%). Sporadic CAs were clearly associated with tobacco smoking, but not with health status. Mutagen sensitivity measured by the BLM test showed significantly (P < 0.04) elevated values not only in HNCPs (1.13 b/c), but also in ALCs (1.29 b/c) as compared with the controls (1.01 b/c). The main finding of the study was that a considerable proportion (46%) of Hungarian controls were mutagen sensitive, twice as many as in those populations reported by others so far. Our data suggest that the BLM test does not characterize susceptibility to cancer due to insignificant differences between HNCPs and ALCs (P = 0.12) under our conditions. However, the assay might be used as a biomarker to predict cancer susceptibility under circumstances when aberrant cell frequency is ≥2% and b/c is ≥1.Keywords
This publication has 17 references indexed in Scilit:
- Genetic polymorphisms of DNA repair and xenobiotic-metabolizing enzymes: role in mutagen sensitivityCarcinogenesis, 2002
- Projections of alcohol- and tobacco-related cancer mortality in Central EuropeInternational Journal of Cancer, 2000
- Prevalence of founderBRCA1 andBRCA2 mutations among breast and ovarian cancer patients in hungaryInternational Journal of Cancer, 2000
- Family history of cancer, mutagen sensitivity, and increased risk of head and neck cancerCancer Letters, 1999
- Genetic polymorphism of drug-metabolizing enzymes and susceptibility to oral cancerCarcinogenesis, 1999
- Polymorphisms of the CYP1A1 and GSTM1 gene involved in oral squamous cell carcinoma in association with a cigarette doseOral Oncology, 1999
- Cytogenetic study of radiation burden in thyroid disease patients treated with external irradiation or radioiodineMutation Research/Environmental Mutagenesis and Related Subjects, 1996
- Sensitivity to genotoxic effects of bleomycin in humans: Possible relationship to environmental carcinogenesisInternational Journal of Cancer, 1989
- Detection of 6-thioguanine resistance in human peripheral blood lymphocytes (PBL) of industrial workers and lung cancer patientsMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1989
- Differential mutagen susceptibility in cultured lymphocytes of normal individuals and cancer patientsCancer Genetics and Cytogenetics, 1985